Vyriad, Inc.
A Phase 1, first in human, study to evaluate the safety and the effects of in vivo BCMA-CAR T cell therapy (VV169) in patients with Multiple Myeloma that has been previously treated and has come back, or does not respond to standard treatments. Eligible patients will receive VV169, a T-cell targeted lentiviral vector, via infusion. Patients will be monitored for safety and tolerability for up to 2 years, until progressive disease or start of next treatment, whichever is earlier.
Eligible patients will be recruited into either the dose escalation phase or dose expansion phase. Eligible patients will be adults who have received prior therapy, or are ineligible for, or did not tolerate standard approved treatment and have no available therapies open to them are eligible. Additional patients will be recruited in the expansion phase once an optimal dose has been identified. In the expansion phase, T cell engagers therapies and anti-BCMA ADC \> 6 months prior, and CAR-T therapy received \> 9 months prior to study enrollment will be permitted.
Inclusion Criteria: 1. Able and willing to sign the informed consent form and comply with the protocol and the restrictions and assessments therein. 2. ≥ 18 years of age. 3. Active relapsed or refractory multiple myeloma with at least 3 prior lines of therapy, OR ineligible for or did not tolerate standard approved treatment and have no available therapies open to them. 1. For Dose Escalation Phase: No prior T-cell engager therapies. No prior BCMA targeting antibody-drug conjugate (ADC) therapy. CAR-T therapy received ≥2 years prior to study enrollment is permitted. 2. For Expansion Ph…
T-cell Targeted (CD3- targeted lentiviral vector)
Arctuva estimate
Verify or correct the compensation shown for this listing.